Get the Stockscreener App
52.63
1.53%
-0.82
After Hours:
52.63
Globus Medical Inc stock is traded at $52.63, with a volume of 1.18M.
It is down -1.53% in the last 24 hours and down -10.83% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$53.45
Open:
$53.09
24h Volume:
1.18M
Relative Volume:
0.74
Market Cap:
$7.13B
Revenue:
$2.51B
Net Income/Loss:
$185.56M
P/E Ratio:
39.28
EPS:
1.34
Net Cash Flow:
$517.59M
1W Performance:
-1.24%
1M Performance:
-10.83%
6M Performance:
-43.24%
1Y Performance:
-26.86%
1-Day Range:
$52.55
$53.31
1-Week Range:
$52.55
$54.78
52-Week Range:
$51.87
$94.93
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
52.63 | 7.24B | 2.51B | 185.56M | 517.59M | 1.34 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Does Globus Medical Inc. stock perform well during market downturnsBest Dividend Guidance For Fast Growth - jammulinksnews.com
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Technical Bounce Expected in Globus Medical Inc. Next WeekTrade Setups With AI Powered Filters Published - metal.it
Globus Medical Inc. Testing Reversal Zone on Weekly ChartOptimized Watchlist With Daily Adjustments Launched - metal.it
Price Action Confirms Reversal in Globus Medical Inc. TrendSecure Capital Picks With Upside Potential Tracked - metal.it
How strong is Globus Medical Inc. company’s balance sheetMarket Forecast Opportunities For Every Investor - jammulinksnews.com
Canaccord Downgrades Globus Medical (GMED) PT to $90, Maintains Buy Rating - MSN
Real time social sentiment graph for Globus Medical Inc. Free ROI Driven Equity Selection With Safety - metal.it
What catalysts could drive Globus Medical Inc. stock higher in 2025Invest smarter with real-time trading alerts - jammulinksnews.com
What are Globus Medical Inc. company’s key revenue driversBest Dividend Updates From AI Tools - jammulinksnews.com
Why Globus Medical Inc. stock attracts strong analyst attentionShort Term Profit Focus - metal.it
When is Globus Medical Inc. stock expected to show significant growthConsistent high-yield stocks - jammulinksnews.com
What makes Globus Medical Inc. stock price move sharplyBuild a portfolio that outperforms the market - jammulinksnews.com
Globus Medical Names Keith Pfeil as CEO, Posts Strong Q2 Sales Growth - MSN
Is Globus Medical Inc. a good long term investmentSuperior stock selection - PrintWeekIndia
Globus Medical Introduces DuraPro with Navigation to Enhance Surgical Workflows, Safety - MSN
What drives Globus Medical Inc. stock priceHigh-yield growth strategies - PrintWeekIndia
Orthobiologics Market Growth in Future Scope 2025-2032 | Zimmer Biomet, Bone Biologics Corp., Globus Medical - openPR.com
What analysts say about Globus Medical Inc. stockFree Predictions - jammulinksnews.com
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply - MedTech Dive
Globus Medical Inc. Stock Analysis and ForecastFree Stock Market Mentorship - jammulinksnews.com
Globus Medical to Announce Q2 2025 Financial Results on August 7, Followed by Investor Call - MSN
Spinal Non-Fusion Technologies Market Set to Witness - openPR.com
Hold Rating on Globus Medical Amid Management Changes and Spine Business Concerns - TipRanks
Globus Medical CEO leaves for Dentsply Sirona corner office - MassDevice
Globus Medical Appoints Keith Pfeil as CEO - citybiz
Avantor and Globus Medical appoint new CEOs - The Business Journals
What You Can Learn From Globus Medical, Inc.'s (NYSE:GMED) P/E - simplywall.st
Why Globus Medical (GMED) Shares Are Trading Lower Today - TradingView
Globus Medical stock holds steady as Needham maintains rating amid CEO change - Investing.com Canada
Globus CEO leaving, analysts see replacement as steady hand - BioWorld MedTech
Globus Medical's Leadership Transition: A Strategic Catalyst for Long-Term Growth in the Medical Technology Sector - AInvest
Globus Medical's Leadership Transition and Growth Potential in a Post-Merger Landscape - AInvest
Keith Pfeil to Lead Globus Medical (GMED) as CEO from July 2025 - GuruFocus
Globus Medical stock hits 52-week low at 53.54 USD By Investing.com - Investing.com Canada
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):